News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.


CRISPR Therapeutics (NASDAQ: CRSP) today announced that it is commencing an underwritten public offering of $325,000,000 of common shares. In addition, the underwriters will have a 30-day option to purchase up to an additional $48,750,000 of common shares at the public offering price less the underwriting discount.

Goldman Sachs & Co. LLC, BofA Securities and Jefferies are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.



Source link